HK1064585A1 - Improved chelator conjugates. - Google Patents

Improved chelator conjugates.

Info

Publication number
HK1064585A1
HK1064585A1 HK04107295A HK04107295A HK1064585A1 HK 1064585 A1 HK1064585 A1 HK 1064585A1 HK 04107295 A HK04107295 A HK 04107295A HK 04107295 A HK04107295 A HK 04107295A HK 1064585 A1 HK1064585 A1 HK 1064585A1
Authority
HK
Hong Kong
Prior art keywords
chelator conjugates
improved
improved chelator
radiometal
conjugates
Prior art date
Application number
HK04107295A
Other languages
English (en)
Inventor
Colin Mill Archer
Harry John Wadsworth
Torgrim Engell
Original Assignee
Ge Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ge Healthcare Ltd filed Critical Ge Healthcare Ltd
Publication of HK1064585A1 publication Critical patent/HK1064585A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C251/36—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atoms of the oxyimino groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Optics & Photonics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
HK04107295A 2001-07-10 2004-09-22 Improved chelator conjugates. HK1064585A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0116815.2A GB0116815D0 (en) 2001-07-10 2001-07-10 Improved chelator conjugates
PCT/GB2002/003168 WO2003006070A2 (fr) 2001-07-10 2002-07-10 Conjugues de chelateurs ameliores

Publications (1)

Publication Number Publication Date
HK1064585A1 true HK1064585A1 (en) 2005-02-04

Family

ID=9918227

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04107295A HK1064585A1 (en) 2001-07-10 2004-09-22 Improved chelator conjugates.

Country Status (21)

Country Link
US (2) US7597875B2 (fr)
EP (1) EP1404377B1 (fr)
JP (1) JP5015409B2 (fr)
KR (1) KR100892009B1 (fr)
CN (4) CN101538313A (fr)
AT (1) ATE304866T1 (fr)
AU (1) AU2002317317B2 (fr)
BR (1) BR0210965A (fr)
CA (1) CA2450690C (fr)
DE (1) DE60206272T2 (fr)
DK (1) DK1404377T3 (fr)
ES (1) ES2250671T3 (fr)
GB (1) GB0116815D0 (fr)
HK (1) HK1064585A1 (fr)
HU (1) HU228850B1 (fr)
IL (1) IL159388A0 (fr)
MX (1) MXPA04000210A (fr)
NO (1) NO334093B1 (fr)
RU (1) RU2298012C2 (fr)
WO (1) WO2003006070A2 (fr)
ZA (1) ZA200400143B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2433657A1 (fr) * 2001-01-05 2002-07-11 Duke University Agent ameliorateur de contraste en imagerie par resonance magnetique
RU2303042C2 (ru) * 2001-07-10 2007-07-20 Джи-И Хелткер АС Соединения на основе пептидов для направленной доставки к рецепторам интегринов
NO20030115D0 (no) 2003-01-09 2003-01-09 Amersham Health As Kontrastmiddel
GB0416062D0 (en) 2004-07-19 2004-08-18 Amersham Plc Improved N4 chelator conjugates
WO2005044313A2 (fr) * 2003-11-06 2005-05-19 Amersham Health As Composes pharmaceutiques
US7431914B2 (en) 2003-11-24 2008-10-07 Ge Healthcare As Contrast agent
EP1729823B1 (fr) * 2004-03-04 2009-11-04 GE Healthcare AS Conjugues comprenant analogues peptidiques d'angiotensin et agents de chelation pour la therapie et le diagnostic
KR20070091609A (ko) * 2004-11-22 2007-09-11 지이 헬스케어 에이에스 세포외 기질을 표적화하기 위한 조영제
WO2006131803A2 (fr) * 2005-06-08 2006-12-14 Ge Healthcare Limited Procede d'utilisation de monoxyde de carbone [11c] dans le marquage de la synthese d'esters et d'acides marques 11c-par carbonylation radicalaire sensibilisee photoinduite
GB0515974D0 (en) * 2005-08-03 2005-09-07 Ge Healthcare Ltd Compounds and imaging methods
ES2357861T3 (es) 2006-02-15 2011-05-03 Ge Healthcare As Agentes de contraste.
US7943117B2 (en) * 2006-06-08 2011-05-17 Atomic Energy Council—Institute of Nuclear Research Method for testing radiochemical purity of Tc-99m-TRODAT-1
EP2101826B1 (fr) * 2006-12-11 2010-06-23 GE Healthcare AS Composés à base de peptides marqués radioactivement et leurs utilisations
CN102300866B (zh) * 2008-12-02 2015-08-26 墨尔本大学 作为放射性药物的含氮大环共轭物
GB0922014D0 (en) 2009-12-17 2010-02-03 Ge Healthcare Ltd Novel integrin binders
CN107362376A (zh) * 2010-07-27 2017-11-21 通用电气健康护理有限公司 放射性药物组合物
GB201103696D0 (en) * 2011-03-04 2011-04-20 Ge Healthcare Ltd Technetium labelled peptides
GB201110767D0 (en) 2011-06-24 2011-08-10 Ge Healthcare Ltd Infection imaging
US20130195756A1 (en) * 2012-01-31 2013-08-01 General Electric Company 99mTc IMAGING AGENTS AND METHODS OF USE
WO2014126902A1 (fr) * 2013-02-15 2014-08-21 Thomas Jefferson University Kit pour imagerie d'une tumeur
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
GB201322456D0 (en) 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
PT3131585T (pt) 2014-03-19 2020-10-23 Univ Zuerich Agentes quelantes bifuncionais multidentados para complexação de radionuclídeos em diagnóstico e terapia
WO2019217571A1 (fr) * 2018-05-08 2019-11-14 University Of Miami Matériaux et procédés pour l'administration d'acides nucléiques thérapeutiques à des tissus
WO2019222454A1 (fr) 2018-05-16 2019-11-21 Emory University Dérivés de styrylbenzothiazole et leurs utilisations en imagerie
CN111548275A (zh) * 2020-05-27 2020-08-18 龙曦宁（上海）医药科技有限公司 一种2-（氨基甲基）-n1,n1-二甲基丙烷-1,3-二胺三盐酸盐的合成方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1588978A (en) * 1977-07-19 1981-05-07 Ici Ltd Coating processes
DE3930674A1 (de) * 1989-09-11 1991-03-21 Diagnostikforschung Inst Bifunktionelle chelatbildner zur komplexierung von tc- und re-isotopen, verfahren zu ihrer herstellung und darstellung von konjugaten daraus sowie deren verwendung in diagnostik und therapie
US5808091A (en) * 1991-10-29 1998-09-15 Bracco International B.V. Rhenium and technetium complexes containing a hypoxia localizing moiety
CA2168652A1 (fr) * 1993-08-04 1995-02-16 Colin Mill Archer Complexes radiometalliques qui se localisent dans le tissu hypoxique
WO1995019187A1 (fr) * 1994-01-12 1995-07-20 Amersham International Plc Agents biologiques de ciblage
ES2114735T3 (es) * 1994-01-12 1998-06-01 Bracco Int Bv Ligandos y complejos metalicos de los mismos.
ATE384075T1 (de) 1998-05-15 2008-02-15 Ge Healthcare Ltd Markierte glutamin- und lysinanaloge
US6783711B2 (en) * 2000-05-23 2004-08-31 Ge Osmonics, Inc. Process for preparing a sulfonamide polymer matrix
WO2002072718A1 (fr) * 2001-03-08 2002-09-19 Matsushita Electric Industrial Co., Ltd. Encre d'impression a jet d'encre, procede de production de l'encre, cartouche d'encre et dispositif d'impression comportant cette encre

Also Published As

Publication number Publication date
CN101607913B (zh) 2012-07-04
EP1404377A2 (fr) 2004-04-07
WO2003006070A3 (fr) 2003-08-21
WO2003006070A2 (fr) 2003-01-23
NO20035597L (no) 2004-03-03
DK1404377T3 (da) 2006-01-30
IL159388A0 (en) 2004-06-01
BR0210965A (pt) 2004-06-08
ES2250671T3 (es) 2006-04-16
AU2002317317B2 (en) 2005-11-17
CN1527727A (zh) 2004-09-08
CA2450690A1 (fr) 2003-01-23
DE60206272D1 (de) 2005-10-27
HU228850B1 (en) 2013-06-28
KR20040017287A (ko) 2004-02-26
KR100892009B1 (ko) 2009-04-07
CN101538313A (zh) 2009-09-23
ZA200400143B (en) 2004-12-29
US20100040542A1 (en) 2010-02-18
MXPA04000210A (es) 2004-07-23
JP5015409B2 (ja) 2012-08-29
US8852550B2 (en) 2014-10-07
HUP0401265A2 (hu) 2004-09-28
GB0116815D0 (en) 2001-08-29
JP2005500325A (ja) 2005-01-06
HUP0401265A3 (en) 2005-11-28
DE60206272T2 (de) 2006-07-13
NO334093B1 (no) 2013-12-09
US20040258619A1 (en) 2004-12-23
EP1404377B1 (fr) 2005-09-21
ATE304866T1 (de) 2005-10-15
CN101607913A (zh) 2009-12-23
RU2298012C2 (ru) 2007-04-27
CA2450690C (fr) 2009-03-24
RU2003137592A (ru) 2005-05-20
US7597875B2 (en) 2009-10-06
NO20035597D0 (no) 2003-12-16
CN101537190A (zh) 2009-09-23
CN100509061C (zh) 2009-07-08

Similar Documents

Publication Publication Date Title
ZA200400143B (en) Improved chelator conjugates.
MXPA05009682A (es) Metodos de radiofluorinacion de vectores biologicamente activos.
PT1791571E (pt) Péptidos radiofluorados
YU27403A (sh) Postupak za pripremanje preparata u obliku praha
MXPA03006093A (es) Derivados de n(fenilsulfonil)glicina y su uso terapeutico.
HK1068626A1 (en) Chemical compounds
TW200716605A (en) 2,6-quinolinyl derivatives, processes for preparing them and their uses
TWI268278B (en) 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses
WO2003104425A3 (fr) Nouveaux anticorps anti-cd22 stables
PL1831239T3 (pl) Sposób wytwarzania gamma-laktonu kwasu 17-hydroksy-6 beta, 7 beta,15 beta, 16 beta-bismetyleno-17 alpha-pregn-4-en-3-ono-21-karboksylowego i związki pośrednie kluczowe dla tego sposobu
GB0105224D0 (en) Improved peptide-chelate conjugates
TW200732345A (en) Niobium compound
DE60322562D1 (de) Konjugate von tc komplexen und zielgerichtete einheiten und ihre verwendung in nmr-diagnostik
PL352104A1 (en) Oral composition containing perlite
ID27733A (id) Metoksiminofenilasetamida
MXPA05008108A (es) Exo-(2r)(+))-2-amino-7-azabiciclo[2.2.1]heptan-7-carboxilato de terc-butilo, compuestos intermedios y procedimiento para prepararlos y aislarlos.
NO20021429L (no) 1,4-dioksacykloalkan-2-oner og 1,4-dioksacykloalken-2-oner
ITMI20030827A1 (it) Composizione farmaceutica contenente l'associazione levodopa/carbidopa.
TW200407314A (en) Preparation of 4, 6-dichloro-5-fluoropyrimidine
UA86379C2 (ru) Азотосодержащие гетероарильные соединения и их применение при повышении эндогенного эритропоэтина
BG103595A (en) Metoprolol compound and methods for its preparation
TW200519206A (en) Methods for producing novel medaka and novel medaka

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20140710